Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir-A Literature Review

Area of Science:

• Infectious Diseases
• Pharmacology
• Public Health

Background:

• COVID-19 poses a significant risk for severe disease progression in certain populations.
• Oral antiviral treatments are crucial for managing mild to moderate COVID-19 cases.
• Nirmatrelvir/Ritonavir is an accessible oral therapeutic for high-risk individuals.

Purpose of the Study:

• To review and summarize current data on Nirmatrelvir/Ritonavir's efficacy in preventing severe COVID-19.
• To compare treatment outcomes between patients receiving Nirmatrelvir/Ritonavir and control groups.
• To assess the drug's effectiveness across different COVID-19 variants and patient demographics.

Main Methods:

• Comprehensive literature review of relevant studies.
• Analysis of publications comparing Nirmatrelvir/Ritonavir with control groups.
• Stratification of data based on COVID-19 variants (Delta, Omicron) and vaccination status.

Main Results:

• During the Delta variant period, Nirmatrelvir/Ritonavir reduced hospitalization or death by 88.9% in unvaccinated, high-risk individuals.
• During the Omicron variant period, relative risk reduction for hospitalization ranged from 26% to 65%.
• Unvaccinated patients showed greater benefit from Nirmatrelvir/Ritonavir compared to vaccinated individuals.

Conclusions:

• Nirmatrelvir/Ritonavir is a valuable tool for reducing severe COVID-19, though its efficacy varies by variant and vaccination status.
• The drug complements, but does not replace, COVID-19 vaccination.
• Low cost and ease of administration make Nirmatrelvir/Ritonavir particularly important for regions with low vaccination rates.